Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice.

Autor: Kim E; Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15224, USA., Okada K; Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15224, USA., Kenniston T; Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15224, USA., Raj VS; Department of Viroscience, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands., AlHajri MM; Supreme Council of Health, Doha, Qatar., Farag EA; Supreme Council of Health, Doha, Qatar., AlHajri F; Animal Resources Department - Ministry of Environment, Doha, Qatar., Osterhaus AD; Department of Viroscience, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands., Haagmans BL; Department of Viroscience, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands., Gambotto A; Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15224, USA. Electronic address: gambottoa@upmc.edu.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2014 Oct 14; Vol. 32 (45), pp. 5975-82. Date of Electronic Publication: 2014 Sep 03.
DOI: 10.1016/j.vaccine.2014.08.058
Abstrakt: A new type of coronavirus has been identified as the causative agent underlying Middle East Respiratory Syndrome (MERS). The MERS coronavirus (MERS-CoV) has spread in the Middle East, but cases originating in the Middle East have also occurred in the European Union and the USA. Eight hundred and thirty-seven cases of MERS-CoV infection have been confirmed to date, including 291 deaths. MERS-CoV has infected dromedary camel populations in the Middle East at high rates, representing an immediate source of human infection. The MERS-CoV spike (S) protein, a characteristic structural component of the viral envelope, is considered as a key target of vaccines against coronavirus infection. In an initial attempt to develop a MERS-CoV vaccine to ultimately target dromedary camels, we constructed two recombinant adenoviral vectors encoding the full-length MERS-CoV S protein (Ad5.MERS-S) and the S1 extracellular domain of S protein (Ad5.MERS-S1). BALB/c mice were immunized with both candidate vaccines intramuscularly and boosted three weeks later intranasally. All the vaccinated animals had antibody responses against spike protein, which neutralized MERS-CoV in vitro. These results show that an adenoviral-based vaccine can induce MERS-CoV-specific immune responses in mice and hold promise for the development of a preventive vaccine that targets the animal reservoir, which might be an effective measure to eliminate transmission of MERS-CoV to humans.
(Copyright © 2014 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: